Hormone receptor positivity in mammary tumors was not correlated to the presence or absence of the Brca1 allele, but instead to inhibition of Rbf via expression of the TgK18GT121 allele, pointing to differences in Rb pathway regulation as a key determinant between HR-positive and HR-negative models. This evidence concerns the gene BRCA1 and breast cancer.